TNFRSF10B

Da Wikipedia, l'enciclopedia libera.
Recettore del fattore di necrosi tissutale 10B
Struttura chimica
Struttura di TNFRSF10B
Gene
HUGO TNFRSF10B CD262; DR5; KILLER; KILLER/DR5; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9
Entrez 8795
Locus Chr. 8 p21.3
Proteina
OMIM 603612
UniProt O14763

Il recettore del fattore di necrosi tumorale 10B è una proteina recettoriale che, nell'essere umano, è codificata dal gene TNFRSF10B e fa parte della superfamiglia dei recettori del fattore di necrosi tumorale[1].

Struttura[modifica | modifica wikitesto]

Si tratta di un recettore transmembrana provvisto di un death domain citoplasmatico[1].

Funzione[modifica | modifica wikitesto]

Tale recettore può interagire con FADD[2][3], TRAIL[4][5][6] e con le caspasi di tipo 10[2][7] e di tipo 8[2][7]. È coinvolto nel meccanismo di morte cellulare programmata mediato da TRAIL, tuttavia studi condotti sull'omologo gene murino hanno suggerito che, per l'attività di tale sistema di trasduzione del segnale, il legame con FADD sia strettamente necessario[1].

Note[modifica | modifica wikitesto]

  1. ^ a b c Entrez Gene: TNFRSF10B tumor necrosis factor receptor superfamily, member 10b.
  2. ^ a b c Consuelo Gajate, Mollinedo Faustino, Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy in J. Biol. Chem., vol. 280, nº 12, United States, marzo 2005, pp. 11641–7, DOI:10.1074/jbc.M411781200, ISSN 0021-9258.
  3. ^ P M Chaudhary, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L, Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway in Immunity, vol. 7, nº 6, UNITED STATES, dicembre 1997, pp. 821–30, DOI:10.1016/S1074-7613(00)80400-8, ISSN 1074-7613.
  4. ^ A Kaptein, Jansen M, Dilaver G, Kitson J, Dash L, Wang E, Owen M J, Bodmer J L, Tschopp J, Farrow S N, Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3) in FEBS Lett., vol. 485, 2-3, NETHERLANDS, novembre 2000, pp. 135–41, DOI:10.1016/S0014-5793(00)02219-5, ISSN 0014-5793.
  5. ^ H Walczak, Degli-Esposti M A, Johnson R S, Smolak P J, Waugh J Y, Boiani N, Timour M S, Gerhart M J, Schooley K A, Smith C A, Goodwin R G, Rauch C T, TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL in EMBO J., vol. 16, nº 17, ENGLAND, settembre 1997, pp. 5386–97, DOI:10.1093/emboj/16.17.5386, ISSN 0261-4189, PMC 1170170.
  6. ^ S G Hymowitz, Christinger H W, Fuh G, Ultsch M, O'Connell M, Kelley R F, Ashkenazi A, de Vos A M, Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5 in Mol. Cell, vol. 4, nº 4, UNITED STATES, ottobre 1999, pp. 563–71, DOI:10.1016/S1097-2765(00)80207-5, ISSN 1097-2765.
  7. ^ a b M MacFarlane, Ahmad M, Srinivasula S M, Fernandes-Alnemri T, Cohen G M, Alnemri E S, Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL in J. Biol. Chem., vol. 272, nº 41, UNITED STATES, ottobre 1997, pp. 25417–20, DOI:10.1074/jbc.272.41.25417, ISSN 0021-9258.

Approfondimenti[modifica | modifica wikitesto]

  • Abe K, Kurakin A, Mohseni-Maybodi M, et al., The complexity of TNF-related apoptosis-inducing ligand. in Ann. N. Y. Acad. Sci., vol. 926, nº 1, 2001, pp. 52–63, DOI:10.1111/j.1749-6632.2000.tb05598.x, PMID 11193041.
  • Cha SS, Song YL, Oh BH, Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex. in Vitam. Horm., vol. 67, 2004, pp. 1–17, DOI:10.1016/S0083-6729(04)67001-4, PMID 15110168.
  • Kimberley FC, Screaton GR, Following a TRAIL: update on a ligand and its five receptors. in Cell Res., vol. 14, nº 5, 2005, pp. 359–72, DOI:10.1038/sj.cr.7290236, PMID 15538968.
  • Pan G, Ni J, Wei YF, et al., An antagonist decoy receptor and a death domain-containing receptor for TRAIL. in Science, vol. 277, nº 5327, 1997, pp. 815–8, DOI:10.1126/science.277.5327.815, PMID 9242610.
  • Sheridan JP, Marsters SA, Pitti RM, et al., Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. in Science, vol. 277, nº 5327, 1997, pp. 818–21, DOI:10.1126/science.277.5327.818, PMID 9242611.
  • Screaton GR, Mongkolsapaya J, Xu XN, et al., TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. in Curr. Biol., vol. 7, nº 9, 1998, pp. 693–6, DOI:10.1016/S0960-9822(06)00297-1, PMID 9285725.
  • Walczak H, Degli-Esposti MA, Johnson RS, et al., TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. in EMBO J., vol. 16, nº 17, 1997, pp. 5386–97, DOI:10.1093/emboj/16.17.5386, PMC 1170170, PMID 9311998.
  • MacFarlane M, Ahmad M, Srinivasula SM, et al., Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. in J. Biol. Chem., vol. 272, nº 41, 1997, pp. 25417–20, DOI:10.1074/jbc.272.41.25417, PMID 9325248.
  • Wu GS, Burns TF, McDonald ER, et al., KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. in Nat. Genet., vol. 17, nº 2, 1997, pp. 141–3, DOI:10.1038/ng1097-141, PMID 9326928.
  • Schneider P, Bodmer JL, Thome M, et al., Characterization of two receptors for TRAIL. in FEBS Lett., vol. 416, nº 3, 1997, pp. 329–34, DOI:10.1016/S0014-5793(97)01231-3, PMID 9373179.
  • Marsters SA, Sheridan JP, Pitti RM, et al., A novel receptor for Apo2L/TRAIL contains a truncated death domain. in Curr. Biol., vol. 7, nº 12, 1998, pp. 1003–6, DOI:10.1016/S0960-9822(06)00422-2, PMID 9382840.
  • Chaudhary PM, Eby M, Jasmin A, et al., Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. in Immunity, vol. 7, nº 6, 1998, pp. 821–30, DOI:10.1016/S1074-7613(00)80400-8, PMID 9430227.
  • Schneider P, Thome M, Burns K, et al., TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. in Immunity, vol. 7, nº 6, 1998, pp. 831–6, DOI:10.1016/S1074-7613(00)80401-X, PMID 9430228.
  • Pai SI, Wu GS, Ozören N, et al., Rare loss-of-function mutation of a death receptor gene in head and neck cancer. in Cancer Res., vol. 58, nº 16, 1998, pp. 3513–8, PMID 9721851.
  • Arai T, Akiyama Y, Okabe S, et al., Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas. in Cancer Lett., vol. 133, nº 2, 1999, pp. 197–204, DOI:10.1016/S0304-3835(98)00230-4, PMID 10072170.
  • Mongkolsapaya J, Grimes JM, Chen N, et al., Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. in Nat. Struct. Biol., vol. 6, nº 11, 2002, pp. 1048–53, DOI:10.1038/14935, PMID 10542098.
  • Hymowitz SG, Christinger HW, Fuh G, et al., Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. in Mol. Cell, vol. 4, nº 4, 1999, pp. 563–71, DOI:10.1016/S1097-2765(00)80207-5, PMID 10549288.
  • Kuang AA, Diehl GE, Zhang J, Winoto A, FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. in J. Biol. Chem., vol. 275, nº 33, 2000, pp. 25065–8, DOI:10.1074/jbc.C000284200, PMID 10862756.
  • Trauzold A, Wermann H, Arlt A, et al., CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. in Oncogene, vol. 20, nº 31, 2001, pp. 4258–69, DOI:10.1038/sj.onc.1204559, PMID 11464292.

Voci correlate[modifica | modifica wikitesto]